KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to $431000.0.

  • Neogenomics' Cash from Financing Activities fell 3726.35% to $431000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$200.3 million, marking a year-over-year decrease of 441097.72%. This contributed to the annual value of -$200.3 million for FY2025, which is 441097.72% down from last year.
  • Latest data reveals that Neogenomics reported Cash from Financing Activities of $431000.0 as of Q4 2025, which was down 3726.35% from $765000.0 recorded in Q3 2025.
  • Neogenomics' 5-year Cash from Financing Activities high stood at $524.9 million for Q1 2021, and its period low was -$202.4 million during Q2 2025.
  • In the last 5 years, Neogenomics' Cash from Financing Activities had a median value of $1.2 million in 2023 and averaged $27.3 million.
  • In the last 5 years, Neogenomics' Cash from Financing Activities skyrocketed by 8497860.62% in 2021 and then plummeted by 1039669.38% in 2025.
  • Neogenomics' Cash from Financing Activities (Quarter) stood at $2.5 million in 2021, then dropped by 26.75% to $1.8 million in 2022, then dropped by 29.52% to $1.3 million in 2023, then crashed by 45.91% to $687000.0 in 2024, then crashed by 37.26% to $431000.0 in 2025.
  • Its Cash from Financing Activities was $431000.0 in Q4 2025, compared to $765000.0 in Q3 2025 and -$202.4 million in Q2 2025.